Can Erythropoietin Protect the Cerebral Blood Flow and Oxygenation During Simulated Dive?
NCT00265486 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 12
Last updated 2012-05-24
Summary
During facial cooling and especially during breath hold, can mammals - and also humans - elicit a so called dive reflex, causing bradycardia, peripheral vasoconstriction and centralization of blood flow to brain, lungs and heart but the reflex is suppressed by physical activity. The dive reflex can be elicited by breath hold alone and will be more pronounced during simultaneously facial cooling, but not by stimulation of other skin receptors.
The dive reflex has an oxygen conserving effect, because of intense vasoconstriction in both viscera and muscles, and simultaneously with reduction in cardiac output (CO). Therefore plasma lactate will rise, to compensate for the lesser regional blood flow. If one hyperventilates with 100 % oxygen, then the reflex can still be elicited, but it is more pronounced during asphyxia. Experienced sports divers, who has been diving for more than 7-10 years have reduced post apnea acidosis and oxidational stress, but probably also less sensitivity for progressive hypoxia and hypercapnia, because these individuals have a more pronounced dive reflex.
Transcranial Doppler ultrasonography (TCD) gives a reproducibly value for brain perfusion by continuously non-invasive real-time sampling. A single piezo-electrical transducer sends and collects ultrasound through the temporal region of the scull, where it is the thinnest. Hereby can the blood flow of arteria cerebri anterior, media (MCA) and posterior and basilaris be estimated.
With TCD it can be shown that the cerebral blood flow rises in MCA in healthy subjects during facial cooling, with normal ventilation, when resting in a supine position without affecting the systemic blood pressure. Single Photon Emission Computerized Tomography (SPECT)-scanning during normo-baric and hyperbaric pressure of professional divers breathing 100 % oxygen has shown to reduce the cerebral blood flow in several regions of the brain.
But it is yet unknown how brain blood flow and metabolism are affected by an "face immersion dive" and simultaneously prolonged physical activity, and hence a rise in lactate under hyperbaric pressure (3 meters), breathing atmospheric air, similar to the circumstances for trained scuba divers work.
Presumably it will cause a fall in brain blood flow and in time cognitive deficits.
Erythropoietin (rhEPO) is a well known drug, used as doping in sports for about 15 years. So far the only known enhancement in athletic achievement by rhEPO is caused by peripheral improvements and especially blood capability to transport oxygen to the working muscles; this has been documented by a rise in haematocrit. rhEPO has also a neuroprotective effect on neurons in patients with neuron damage caused by cerebral hypoxic ischeamia.
rhEPO work also on a series of cerebral mechanisms, including enhanced motor and spatial learning and more. Enhanced motor learning may improve the professional divers choices during work and may be also physical performance and mechanical efficiency. Intravenous injection of rhEPO will increase rhEPO in cerebrospinal fluids, since rhEPO is capable of crossing blood brain. All together this may indicate that rhEPO, not only works on physical performance, but also has effects on the brain. rhEPO has also an effect on the condition of cancer and dialysis patients, not only explained by merely increased hematocrit.
This project will add new knowledge in the understanding of the mechanisms of clinical use of rhEPO.
The purpose of this study is to investigate, how brain blood flow and metabolism are affected by face immersion dive and simultaneously breath hold during normo-baric and hyperbaric pressure (3 m depth) when breathing atmospheric air in trained sports divers. IL-6, HSP-72, lactate, ammonium and body-temperature will be measured. Brain and muscle oxygenation will be measured by near-infrared spectroscopi (NIRS). Furthermore we will investigate whether a small dose of rhEPO affects mentioned parameters during simulated dive in pressure chamber with facial cooling.
Hypothesis Brain blood flow in trained divers will be diminished during prolonged physical activity during simultaneously face immersion dive and breath hold under hyperbaric pressure.
There will be a release of IL-6 and HSP-72. Pretreatment with a small amount of rhEPO before prolonged physical activity during simulated dive has a protective effect on brain blood flow and oxygenation.
Conditions
- Healthy
Interventions
- DRUG
-
Recombinant human Erythropoietin
Adm 100 U/kg sc 1 hour before completing exercise in protocol
Sponsors & Collaborators
-
Rigshospitalet, Denmark
lead OTHER
Principal Investigators
-
Thomas Kjeld, MD · Rigshospitalet, dept of aneasthesiolgy, 2042, Blegdamsvej, 2100 CPH, DK
Eligibility
- Min Age
- 18 Years
- Max Age
- 40 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2005-08-31
- Primary Completion
- 2012-06-30
- Completion
- 2012-07-31
Countries
- Denmark
Study Locations
More Related Trials
-
Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy
NCT01732146 ·Status: COMPLETED ·Phase: PHASE3
-
Umbilical Cord Blood Mononuclear Cells for Hypoxic Neurologic Injury in Infants With Congenital Diaphragmatic Hernia (CDH)
NCT03526588 ·Status: TERMINATED ·Phase: PHASE1
-
Trial of Maternal Oxygen for Fetal Left Heart Hypoplasia
NCT02965638 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study
NCT00589953 ·Status: TERMINATED ·Phase: PHASE2
-
Survey on the Clinical Use of Recombinant Human Erythropoietin in VLBW and ELBW Infants
NCT05372211 ·Status: UNKNOWN
-
Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic CHD - A Prospective Control Trial
NCT02564796 ·Status: TERMINATED ·Phase: PHASE2
-
Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants
NCT00910234 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Erythropoietin for Infants With Brain Injuries Due to Oxygen Deprivation at Birth
NCT00491413 ·Status: UNKNOWN ·Phase: PHASE1
-
Long Term Effects of Erythropoietin in Patients With Moderate to Severe Traumatic Brain Injury
NCT03061565 ·Status: COMPLETED
-
Effect of Erythropoietin on Preterm Brain Injury
NCT02036073 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in People With Persistent Symptoms During the Subacute Period After Traumatic Brain Injury
NCT02226848 ·Status: WITHDRAWN ·Phase: PHASE2
-
Erythropoietin in Infants With Hypoxic Ischemic Encephalopathy (HIE)
NCT00945789 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Treatment of Premature Infants With Brain Injury by Autologous Umbilical Cord Blood Stem Cells
NCT03696745 ·Status: UNKNOWN ·Phase: PHASE1
-
Neonatal Erythropoietin in Asphyxiated Term Newborns
NCT00719407 ·Status: COMPLETED ·Phase: PHASE1
-
Does Erythropoietin Improve Outcome in Very Preterm Infants?
NCT00413946 ·Status: COMPLETED ·Phase: PHASE2
-
Reoxygenation for Cyanotic Pediatric CHD
NCT03568357 ·Status: UNKNOWN
-
Serum Erythropoietin Level in Perinatal Asphyxia
NCT05018364 ·Status: COMPLETED
-
Autologous Stem Cells in Newborns With Oxygen Deprivation
NCT01506258 ·Status: UNKNOWN ·Phase: NA
-
Effect of Erythropoietin on Neurodevelopmental Outcomes in Very Preterm Infants With Intraventricular Hemorrhage
NCT03914690 ·Status: COMPLETED ·Phase: PHASE2
-
Neurological Outcome After Erythropoietin Treatment for Neonatal Encephalopathy
NCT00808704 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Correlation Between Red Cell Transfusion and Complications of Prematurity
NCT07123948 ·Status: NOT_YET_RECRUITING
-
Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO)
NCT01913340 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of 2-Iminobiotin in Neonates With Perinatal Asphyxia
NCT01626924 ·Status: TERMINATED ·Phase: PHASE2
-
RBC Irradiation, Anemia and Gut Injury
NCT02741648 ·Status: ACTIVE_NOT_RECRUITING
-
Melatonin for Pulmonary Hypertension in Full Term Neonates
NCT06685679 ·Status: COMPLETED ·Phase: PHASE3